<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00161551</url>
  </required_header>
  <id_info>
    <org_study_id>MODEST V.2.2.1</org_study_id>
    <nct_id>NCT00161551</nct_id>
  </id_info>
  <brief_title>Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)</brief_title>
  <official_title>A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic BRC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vitatron GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic BRC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the incidence of atrial fibrillation and heart
      failure in patients with pacemaker therapy with different pacing modes (AAI, DDD, and a novel
      algorithm to minimize ventricular pacing).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Dual-chamber pacemaker therapy has become the mainstay for treating symptomatic
      sick sinus syndrome (SSS). This approach aims to results in a physiologic conduction pattern,
      while protecting against atrioventricular conduction anomalies. Smaller studies and subgroup
      analyses of larger trials suggest that ventricular stimulation associated with this treatment
      has adverse effects, especially an increased incidence of atrial fibrillation and heart
      failure.

      Methods: In MODEST, a study on patients with sick sinus syndrome who have an indication for
      pacing therapy, atrial pacing (AAI) is compared with dual-chamber pacing (DDD) combined with
      a novel algorithm developed to lower the number of ventricularly paced beats. The study aims
      to assess the impact of ventricular pacing on the development of atrial arrhythmias and to
      test the hypothesis that DDD pacing using the algorithm is associated with a higher rate of
      atrial arrhythmias as atrial pacing. Included will be patients with SSS and no high degree AV
      node disease except for patients with first-degree AV block ≤300ms. Patients will be followed
      stratified by their Wenckebach point (≥ 120 bpm versus &lt; 120 bpm).

      Conclusion: MODEST is a large, prospective, randomized, multicenter trial aiming to compare a
      novel type of dual-chamber pacing approach (that includes an algorithm designed to lower the
      number of ventricularly paced beats) with pure atrial pacing, assessing the impact on the
      incidence of atrial arrhythmias in patients with sick sinus syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <completion_date>December 2010</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective is to assess how the pacing mode affects the incidence of atrial fibrillation (AF) in patients with sick sinus syndrome. Since there are no data on the safety of AAI pacing in patients with Wenckebach points &lt; 120 bpm and accor</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with atrial fibrillation or heart failure &gt; NYHA II</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF burden</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic atrial fibrillation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time period to first recurrence of AF</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients without recurrence of AF</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of sinus rhythm</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of Wenckebach point</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second- and third-degree AV block</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reprogramming from AAI to DDD</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of atrial versus ventricular pacing</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment, complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cardioversions</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with persistent atrial fibrillation (AF &gt;48h)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with permanent atrial fibrillation (AF throughout the follow-up period)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions for cardiac reasons</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Sick Sinus Syndrome</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitatron T70 DR</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic sinus bradycardia, Sinusarrest

          -  Symptomatic SA block

          -  Bradycardia-Tachycardia-Syndrome

          -  Binodal diseases

        Exclusion Criteria:

          -  1st degree AV Block

          -  2nd degree AV block

          -  3rd degree AV block

          -  Total right bundle branch block

          -  Indication for biventricular stimulation

          -  Inter atrial conduction delays (P-wave &gt; 150MS)

          -  Permanent or therapy refractory Atrial Fibrillation

          -  Heart Failure acc. NYHA III or IV

          -  Myocardial Infarction less than 6 months before pacemaker implant

          -  Hypertrophic obstructive cardiomyopathy

          -  Symptomatic hypo- or hyperthyreosis

          -  Cardiogenic shock

          -  Pregnancy

          -  Lactation period

          -  Unstable angina pectoris

          -  Poorly controlled Diabetes mellitus

          -  Neuromuscular diseases

          -  Patients under 18 years of age

          -  Patients involved in other studies

          -  Reduced expectancy of life due to other diseases

          -  Patients who cannot attend follow-up visits regularly
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Schibgilla, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Reimers, Dipl. Documentalist</last_name>
    <phone>+49 21152930</phone>
    <email>Matthias.reimers@vitatron.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steffen Gazarek, Dr., Engineer</last_name>
    <phone>+49 1729135662</phone>
    <email>steffen.gazarek@vitatron.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V. Schibgilla, MD</last_name>
      <phone>+49 9561220</phone>
      <phone_ext>6348</phone_ext>
      <email>v.schibgilla@t-online.de</email>
    </contact>
    <investigator>
      <last_name>V. Schibgilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätskrankenhaus Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Schuchert, MD</last_name>
      <phone>+49 40428030</phone>
      <phone_ext>5765</phone_ext>
      <email>schuchert@uke.uni-hamburg.de</email>
    </contact>
    <investigator>
      <last_name>A. Schuchert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kardiologische Gemeinschaftspraxis</name>
      <address>
        <city>Papenburg</city>
        <zip>26871</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Wilke, MD</last_name>
      <phone>+49 4961992013</phone>
      <email>Praxis@Kardiologie-Papenburg.de</email>
    </contact>
    <investigator>
      <last_name>A. Wilke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kardiologische Praxis</name>
      <address>
        <city>Starnberg-Percha</city>
        <zip>82319</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Frey, MD</last_name>
      <phone>+49 8151559055</phone>
      <email>kardiologie-sta@t-online.de</email>
    </contact>
    <investigator>
      <last_name>A. Frey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sophien- und Hufelandklinikum GmbH</name>
      <address>
        <city>Weimar</city>
        <zip>99425</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E. Ebner, PD MD</last_name>
      <phone>+49 3643571100</phone>
      <email>innere1@klinikum-weimar.de</email>
    </contact>
    <investigator>
      <last_name>E. Ebner, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Lamas GA, Orav EJ, Stambler BS, Ellenbogen KA, Sgarbossa EB, Huang SK, Marinchak RA, Estes NA 3rd, Mitchell GF, Lieberman EH, Mangione CM, Goldman L. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N Engl J Med. 1998 Apr 16;338(16):1097-104.</citation>
    <PMID>9545357</PMID>
  </reference>
  <reference>
    <citation>Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, Marinchak RA, Flaker G, Schron E, Orav EJ, Hellkamp AS, Greer S, McAnulty J, Ellenbogen K, Ehlert F, Freedman RA, Estes NA 3rd, Greenspon A, Goldman L; Mode Selection Trial in Sinus-Node Dysfunction. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002 Jun 13;346(24):1854-62.</citation>
    <PMID>12063369</PMID>
  </reference>
  <reference>
    <citation>Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997 Oct 25;350(9086):1210-6.</citation>
    <PMID>9652562</PMID>
  </reference>
  <reference>
    <citation>Nielsen JC, Kristensen L, Andersen HR, Mortensen PT, Pedersen OL, Pedersen AK. A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome. J Am Coll Cardiol. 2003 Aug 20;42(4):614-23.</citation>
    <PMID>12932590</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, Sami MH, Talajic M, Tang AS, Klein GJ, Lau C, Newman DM. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med. 2000 May 11;342(19):1385-91.</citation>
    <PMID>10805823</PMID>
  </reference>
  <reference>
    <citation>Mattioli AV, Vivoli D, Mattioli G. Influence of pacing modalities on the incidence of atrial fibrillation in patients without prior atrial fibrillation. A prospective study. Eur Heart J. 1998 Feb;19(2):282-6.</citation>
    <PMID>9519322</PMID>
  </reference>
  <reference>
    <citation>Kerr CR, Connolly SJ, Abdollah H, Roberts RS, Gent M, Yusuf S, Gillis AM, Tang AS, Talajic M, Klein GJ, Newman DM. Canadian Trial of Physiological Pacing: Effects of physiological pacing during long-term follow-up. Circulation. 2004 Jan 27;109(3):357-62. Epub 2004 Jan 5.</citation>
    <PMID>14707022</PMID>
  </reference>
  <reference>
    <citation>Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A; Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002 Dec 25;288(24):3115-23.</citation>
    <PMID>12495391</PMID>
  </reference>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2011</last_update_posted>
  <keyword>Cardiac Pacing, artificial</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Pacemaker leads</keyword>
  <keyword>Pacing Mode</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Sick Sinus Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

